Contineum Therapeutics, Inc.
CTNM
$4.62
$0.245.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 128.72% | 95.38% | 51.09% | 45.11% | 16.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 76.18% | 60.79% | -1.08% | 94.13% | 77.57% |
| Operating Income | -76.18% | -60.79% | -128.11% | -94.13% | -77.57% |
| Income Before Tax | -83.67% | -61.20% | -121.30% | -74.48% | -5.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -87.48% | -64.25% | -121.68% | -74.48% | -3.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.48% | -64.25% | -121.68% | -74.48% | -3.42% |
| EBIT | -76.18% | -60.79% | -128.11% | -94.13% | -77.57% |
| EBITDA | -76.08% | -60.88% | -127.92% | -95.74% | -79.56% |
| EPS Basic | -10.63% | 85.16% | -108.08% | -2,225.20% | 84.68% |
| Normalized Basic EPS | 83.34% | 85.44% | -102.09% | -67.75% | -1.75% |
| EPS Diluted | -10.63% | 85.13% | -121.73% | -2,225.20% | 84.79% |
| Normalized Diluted EPS | 83.34% | 85.44% | -104.10% | -67.75% | -1.75% |
| Average Basic Shares Outstanding | 1,002.58% | 1,006.86% | 918.87% | 4.02% | 3.75% |
| Average Diluted Shares Outstanding | 1,002.58% | 1,006.86% | 419.26% | 4.02% | 3.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |